Clovis Oncology announces positive hearing for Rubraca in Europe

Clovis Oncology announces positive hearing for Rubraca in Europe

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More

Wednesday December 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, Rucaparib

Clovis Oncology announces second patent for Rucaparib high dose

Clovis Oncology announces second patent for Rucaparib high dose

BOULDER -- Clovis Oncology , Inc. (NASDAQ:CLVS) today announced the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating... Read More

Tuesday November 20, 2018 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy

Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with... Read More

Tuesday May 29, 2018 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rucaparib

Clovis Oncology offering convertible senior notes, stocks to raise up to $345M

Clovis Oncology offering convertible senior notes, stocks to raise up to $345M

BOULDER -- Clovis Oncology, Inc .(NASDAQ:CLVS) announced it has commenced two separate underwritten public offerings of convertible senior notes and common stock to raise a total of $345... Read More

Monday April 16, 2018 0 comments Tags: Boulder, Clovis Oncology, Rucaparib

Clovis: EU Medicines Agency approval sought for rucaparib cancer drug

Clovis: EU Medicines Agency approval sought for rucaparib cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Unions (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that... Read More

Tuesday December 19, 2017 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rucaparib

Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

BOULDER -- Clovis Oncology (NASDAQ: CLVS) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance... Read More

Tuesday October 10, 2017 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey, FDA

Clovis Oncology: Rucaparib improved survival in ovarian cancer patients

Clovis Oncology: Rucaparib improved survival in ovarian cancer patients

BOULDER -- ClovisOncology (NASDAQ: CLVS) today announced toplinedata from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achievedthe primary endpoint of improved... Read More

Monday June 19, 2017 0 comments Tags: Boulder, Clovis Oncology, Patrick Mahaffy, Rucaparib

Clovis announces FDA application for accelerated approval of cancer drug

Clovis announces FDA application for accelerated approval of cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the U.S. Food and Drug Administration (FDA) has accepted Clovis New Drug Application (NDA) for accelerated approval of rucaparib and... Read More

Thursday August 25, 2016 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy, Foundation Medicine